168 related articles for article (PubMed ID: 32707593)
1. Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor.
Yamada H; Ohira H; Ikegami F; Nakamura K; Takahashi A; Abe K; Inano A; Shimada S; Miyata K; Saito T; Ohba Y; Terao K; Ohnishi A
Drug Res (Stuttg); 2020 Sep; 70(9):401-409. PubMed ID: 32707593
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects.
Kasahara-Ito N; Fukase H; Ogama Y; Saito T; Ohba Y; Shimada S; Takano Y; Ichihara T; Terao K; Nakamichi N; Kumagai Y; Ikeda S
Drug Res (Stuttg); 2017 Jun; 67(6):349-357. PubMed ID: 28427104
[TBL] [Abstract][Full Text] [Related]
3. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
[TBL] [Abstract][Full Text] [Related]
4. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
5. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
7. The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Zhang W; Krauwinkel WJ; Keirns J; Townsend RW; Lasseter KC; Plumb L; Kadokura T; Ushigome F; Smulders R
Clin Drug Investig; 2013 Jul; 33(7):489-96. PubMed ID: 23733389
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.
Zell M; Husser C; Kuhlmann O; Schwab D; Uchimura T; Kemei T; Kawashima K; Yamane M; Pähler A
Xenobiotica; 2014 Apr; 44(4):369-78. PubMed ID: 24074237
[TBL] [Abstract][Full Text] [Related]
9. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption.
Ping X; Wang G; Gao D
J Clin Pharmacol; 2024 Jun; 64(6):672-684. PubMed ID: 38363006
[TBL] [Abstract][Full Text] [Related]
11. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
Macha S; Rose P; Mattheus M; Cinca R; Pinnetti S; Broedl UC; Woerle HJ
Diabetes Obes Metab; 2014 Feb; 16(2):118-23. PubMed ID: 23859534
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
14. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Ikeda S; Takano Y; Schwab D; Portron A; Kasahara-Ito N; Saito T; Iida S
Drug Res (Stuttg); 2019 Jun; 69(6):314-322. PubMed ID: 30103216
[TBL] [Abstract][Full Text] [Related]
15. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
[TBL] [Abstract][Full Text] [Related]
18. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
[TBL] [Abstract][Full Text] [Related]
19. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.
Macha S; Jungnik A; Hohl K; Hobson D; Salsali A; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):873-9. PubMed ID: 24152604
[TBL] [Abstract][Full Text] [Related]
20. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Sarashina A; Ueki K; Sasaki T; Tanaka Y; Koiwai K; Sakamoto W; Woerle HJ; Salsali A; Broedl UC; Macha S
Clin Ther; 2014 Nov; 36(11):1606-15. PubMed ID: 25199997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]